Your support for the iCMLf will further the progress towards best possible management for CML patients wherever they reside. In addition, becoming a member of the iCMLf provides a number of benefits.
The mission of the iCMLf is to improve outcomes for people with CML globally. Formed in 2009 by a leading group of hematologists, the aims of the iCMLf are to foster and coordinate global clinical and research collaborations and to improve CML clinical practice and disease monitoring worldwide.
“The improved survival in CML directly attributable to the use of tyrosine kinase inhibitors is so dramatic that these new agents must be made available to the greatest possible number of eligible patients as rapidly as possible throughout the whole world” John Goldman iCMLf Chairman
There are numerous activities that come within the iCMLf’s broad charter but the initial focus of the Foundation is to address the needs in CML that are not already being met by other groups, particularly those needs that are best met by a global organisation. Even in a disease area with effective treatment, so much still needs to be tackled to make sure that all patients around the world receive the best possible therapy and care.
ERSAP Preceptorship Program - Enhancing clinical knowledge and skills in the treatment of CML through preceptorships at internationally renowned CML centres. This program is a unique opportunity for clinicians from emerging economic countries who treat CML to undertake an intensive educational program to develop and expand their CML management skills.
ERSAP Diagnosis and Testing Program - Through this program the iCMLf assists clinicians in emerging regions use objective testing to diagnose and monitor CML via FISH, cytogenetics, or PCR. Partnerships are established between CML doctors and centres in emerging regions and CML centres of excellence to develop diagnostic and monitoring services. Through this program the iCMLf will enhance facilities at a local level, building capacity to bring high quality testing to the patient.
iCMLf Virtual Education Program - A series of webcast presentations on the practical aspects of CML management. Innovative e-learning tutorials are provided as interactive webcasts on the iCMLf website as well as on USB flash drives for offline use. Leading hematologists provide lectures with updated information on treatment advances, including disease monitoring and new therapies.
Through the work of the iCMLf your support will further the progress towards best possible management for CML patients wherever they reside.
Membership of the iCMLf is US$100 annually.
A lesser amount can be contributed if full payment is difficult at this time (minimum $10)
Members of the iCMLf will:
The iCMLf is a charitable organisation registered in England and Wales.
Charity number 1132984.
Donations are tax deducible as allowable by law.
The mission of the iCMLf is to improve outcomes for people with CML globally. Established in 2009 by a leading group of hematologists, the aims of the iCMLf are to foster and coordinate global clinical and research collaborations and to improve CML clinical practice and disease monitoring worldwide. Become a member now!